Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent.

Huang H, Ng CY, Yu D, Zhai J, Lam Y, Soong TW.

Nat Commun. 2014 Jul 24;5:4481. doi: 10.1038/ncomms5481.

2.

Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Labandeira-Garcia JL, Rodriguez-Pallares J, Rodríguez-Perez AI, Garrido-Gil P, Villar-Cheda B, Valenzuela R, Guerra MJ.

Am J Neurodegener Dis. 2012;1(3):226-44. Epub 2012 Nov 18.

3.

Importance of the brain Angiotensin system in Parkinson's disease.

Wright JW, Harding JW.

Parkinsons Dis. 2012;2012:860923. doi: 10.1155/2012/860923. Epub 2012 Nov 7.

4.

Calcium channel blocker use and risk of Parkinson's disease.

Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A.

Mov Disord. 2010 Sep 15;25(12):1818-22. doi: 10.1002/mds.23191.

5.

L-type calcium channel blockers and Parkinson disease in Denmark.

Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S.

Ann Neurol. 2010 May;67(5):600-6. doi: 10.1002/ana.21937.

6.

Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Gagne JJ, Power MC.

Neurology. 2010 Mar 23;74(12):995-1002. doi: 10.1212/WNL.0b013e3181d5a4a3. Review.

Supplemental Content

Support Center